Patents by Inventor Chad Brokopp

Chad Brokopp has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20180022822
    Abstract: Provided are novel human-derived antibodies specific for Fibroblast Activation Protein (FAP), preferably capable of selectively inhibiting the enzymatic activity of FAP, and chimeric antigen receptors (CARs) directed against the human FAP antigen as well as methods related thereto. In addition, methods of diagnosing and/or monitoring diseases and treatments thereof which are associated with FAP are provided. Assays and kits related to antibodies specific for FAP are also disclosed. The novel anti-FAP antibodies can be used in pharmaceutical and diagnostic compositions for FAP-targeted immunotherapy and diagnostics.
    Type: Application
    Filed: July 12, 2017
    Publication date: January 25, 2018
    Inventors: Chad BROKOPP, Jan Grimm, Benoit Combaluzier, Manuel Tobias Gersbacher
  • Publication number: 20180009907
    Abstract: Methods for diagnosing inflammatory and/or cardiovascular diseases by assaying for Fibroblast Activation Protein (FAP) expression in a body fluid is provided as well as therapeutic means based thereon.
    Type: Application
    Filed: September 15, 2017
    Publication date: January 11, 2018
    Inventors: Chad Brokopp, Simon Hoerstrup
  • Publication number: 20170369592
    Abstract: Provided are novel human-derived antibodies specific for Fibroblast Activation Protein (FAP), preferably capable of selectively inhibiting the enzymatic activity of FAP, as well as methods related thereto. In addition, methods of diagnosing and/or monitoring diseases and treatments thereof which are associated with FAP are provided. Assays and kits related to antibodies specific for FAP are also disclosed. The novel anti-FAP antibodies can be used in pharmaceutical and diagnostic compositions for FAP-targeted immunotherapy and diagnostics.
    Type: Application
    Filed: January 11, 2016
    Publication date: December 28, 2017
    Applicants: Mabimmune Diagostics AG, Neurimmune Holding AG, University of Zurich
    Inventors: Chad BROKOPP, Jan GRIMM, Benoit COMBALUZIER, Mareike GOERANSON, Christine LOHMANN, Simon HOERSTRUP, Roger NITSCH
  • Publication number: 20150329646
    Abstract: Methods for diagnosing inflammatory and/or cardiovascular diseases by assaying for Fibroblast Activation Protein (FAP) expression in a body fluid is provided as well as therapeutic means based thereon.
    Type: Application
    Filed: May 11, 2015
    Publication date: November 19, 2015
    Inventors: Chad Brokopp, Simon Hoerstrup
  • Patent number: 9034333
    Abstract: A novel method for validating the utility of a drug in the treatment of inflammatory and cardiovascular diseases is described.
    Type: Grant
    Filed: August 29, 2011
    Date of Patent: May 19, 2015
    Assignee: University of Zurich
    Inventors: Chad Brokopp, Simon Hoerstrup
  • Publication number: 20130164305
    Abstract: A novel method for validating the utility of a drug in the treatment of inflammatory and cardiovascular diseases is described.
    Type: Application
    Filed: August 29, 2011
    Publication date: June 27, 2013
    Applicant: University of Zurich
    Inventors: Chad Brokopp, Simon Hoerstrup
  • Publication number: 20130156785
    Abstract: Methods for diagnosing inflammatory and/or cardiovascular diseases by assaying for Fibroblast Activation Protein (FAP) expression in a body fluid is provided as well as therapeutic means based thereon.
    Type: Application
    Filed: August 29, 2011
    Publication date: June 20, 2013
    Applicant: UNIVERSITY OF ZURICH
    Inventors: Chad Brokopp, Simon Hoerstrup